The IPS scores of four various subtypes (CTLA4_neg_PD1_neg, CTLA4_pos_PD1_neg, CTLA4_neg_PD1_pos, and CTLA4_pos_PD1_pos) were applied to predict the response of the melanoma patients to anti-CTLA4 and anti-PD1 treatment. This evidence concerns the gene PDCD1 and melanoma.